March 12 (Reuters) - Agile Therapeutics Inc ::AGILE THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.18.Q4 EARNINGS PER SHARE VIEW $-0.24 -- THOMSON REUTERS I/B/E/S.AGILE THERAPEUTICS - BELIEVES CASH AND CASH EQUIVALENTS AS OF DEC 31, 2017, TO BE SUFFICIENT TO MEET ITS OPERATING REQUIREMENTS THROUGH END OF 2018.
Full Article
Jan 9 (Reuters) - Perceptive Advisors LLC::Perceptive Advisors LLC Reports A 9.9 Pct Passive Stake In Agile Therapeutics Inc <<>> As Of Dec 22, 2017 - SEC Filing.
Full Article
Dec 22 (Reuters) - Agile Therapeutics Inc ::AGILE THERAPEUTICS, INC. RECEIVES A COMPLETE RESPONSE LETTER FROM THE FDA FOR TWIRLA® (AG200-15) FOR THE PREVENTION OF PREGNANCY.AGILE THERAPEUTICS - CRL STATES THAT FDA HAS DETERMINED THAT IT CANNOT APPROVE NDA FOR TWIRLA ITS PRESENT FORM.AGILE THERAPEUTICS INC - CRL IDENTIFIES DEFICIENCIES RELATING TO QUALITY ADHESION TEST METHODS.AGILE THERAPEUTICS-FDA INDICATED APPLICABLE SECTIONS OF AMENDED NDA SUBMITTED BY CO COULD BE INCORPORATED WHEN RESPONDING TO DEFICIENCIES NOTED IN CRL.AGILE THERAPEUTICS - CRL ALSO NOTED THAT OBSERVATIONS IDENTIFIED DURING INSPECTION OF A FACILITY OF CORIUM INTERNATIONAL FOR TWIRLA NDA MUST BE RESOLVED.AGILE THERAPEUTICS INC - CRL DOES NOT IDENTIFY ANY SPECIFIC ISSUES RELATING TO SAFETY OF TWIRLA.AGILE THERAPEUTICS SAYS CRL RECOMMENDS THAT CO ASSESS IN VIVO ADHESION PROPERTIES DEMONSTRATED IN SECURE CLINICAL TRIAL.AGILE THERAPEUTICS - CRL "QUESTIONS" THE IN VIVO ADHESION PROPERTIES OF TWIRLA & THEIR POTENTIAL RELATIONSHIP TO SECURE PHASE 3 CLINICAL TRIAL RESULTS.AGILE THERAPEUTICS INC - "WE ARE EVALUATING THE FDA'S RESPONSE".
Full Article
Nov 6 (Reuters) - Agile Therapeutics Inc :Agile therapeutics reports third quarter 2017 financial results.Q3 loss per share $0.22.Q3 earnings per share view $-0.24 -- Thomson Reuters I/B/E/S.Agile Therapeutics Inc - PDUFA goal date for Twirla is December 26, 2017.Agile Therapeutics - believes cash, cash equivalents as of sept. 30, will be sufficient to meet its operating requirements into Q2 of 2018.
Full Article
Agile Therapeutics Inc : On October 5, 2016, board appointed Al Altomari, president and CEO, as chairman of board effective immediately - SEC filing Source: (http://bit.ly/2dOmS1B) Further company coverage: [AGRX.O] ((bangalore.newsroom@thomsonreuters.com;)).
Full Article
Agile Therapeutics Inc : Entered into first amendment to loan and security agreement with Hercules Capital, Inc, other banks,other financial institutions . First amendment extends interest-only payments until January 31, 2017 in connection with first tranche of $16.5 million of term loan .Amendment extends co's option to draw down second tranche of $8.5 million of term loan facility provided under loan agreement until Mar 31,2017.
Full Article
Agile Therapeutics Inc : Agile Therapeutics reports second quarter 2016 financial results . Q2 earnings per share view $-0.29 -- Thomson Reuters I/B/E/S . Q2 loss per share $0.29 . Says as of june 30, 2016 $59.2 million of cash and cash equivalents compared to $34.4 million as of december 31, 2015 .Says cash and cash equivalents will be sufficient to meet its operating requirements through end of 2017.
Full Article
Agile Therapeutics Inc : Cash expected to fund operations through end of 2017 . Agile therapeutics reports first quarter 2016 financial results . Q1 loss per share $0.27 .Q1 earnings per share view $-0.38 -- Thomson Reuters I/B/E/S.
Full Article
Earnings vs. 
Estimates